Figures & data
Table 1. Demographic and baseline characteristics of the ITT population and LEN-relapsed or -refractory subgroups.
Table 2. Response by mIMWG criteria in the ITT population and LEN-relapsed or -refractory subgroups.
Figure 1. Kaplan-Meier estimates of PFS in the ITT population (A), by lenalidomide-relapsed or -refractory status (B), and by prior line of therapy (C). ITT: intention-to-treat; NE: not estimable; PFS: progression-free survival.
![Figure 1. Kaplan-Meier estimates of PFS in the ITT population (A), by lenalidomide-relapsed or -refractory status (B), and by prior line of therapy (C). ITT: intention-to-treat; NE: not estimable; PFS: progression-free survival.](/cms/asset/77368add-c006-4b2e-b1b1-86a5fecbcf10/ilal_a_2030477_f0001_c.jpg)
Table 3. Select grade 3/4 TEAEs in the safety population.
Figure 2. Mean change from baseline in EQ-5D at cycle 12. ECOG PS: Eastern Cooperative Oncology Group performance status; IMWG: International Myeloma Working Group; LCL: lower confidence limit; LEN: lenalidomide; R-ISS: revised International Staging System; SCT: stem cell transplant; Tx: treatment; UCL: upper confidence limit.
![Figure 2. Mean change from baseline in EQ-5D at cycle 12. ECOG PS: Eastern Cooperative Oncology Group performance status; IMWG: International Myeloma Working Group; LCL: lower confidence limit; LEN: lenalidomide; R-ISS: revised International Staging System; SCT: stem cell transplant; Tx: treatment; UCL: upper confidence limit.](/cms/asset/03078fcf-9ba2-42ab-95c3-78c174be662a/ilal_a_2030477_f0002_c.jpg)
GLAL-2021-1033-File010.docx
Download MS Word (158.2 KB)Data availability statement
BMS policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html.